Andera Partners, a private equity firm, led a €39m Series A funding round in TargED Biopharmaceuticals, a biopharmaceutical company, with participation from Hadean Ventures, Inkef Capital and Sunstone Life Science Ventures, and joined by existing investors FIRST (Managed by BioGeneration Ventures), Curie Capital and Utrecht Health Seed Fund. “We are delighted to have the support of this international syndicate of world class life science investors, a validation of the potential of Microlyse. We are proud to be developing products that have the potential to positively impact millions of lives by enabling patient access to such lifesaving treatment," Kristof Vercruysse, TargED CEO.